EPI Health and MC2 Therapeutics Announce Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) now covered on Express Scripts National Preferred Formulary
POSTED: November 9, 2021
Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once- daily topical treatment of plaque psoriasis in adults 18 years of age or older
CHARLESTON, SC, USA and ...
READ FULL ARTICLE >
MC2 Therapeutics’ clinical research to be presented in four poster presentations at the European Academy of Dermatology and Venereology conference - EADV 2021
POSTED: September 29, 2021
- Poster # P1447: A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment ...
READ FULL ARTICLE >
Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to WYNZORA® Cream for treatment of Plaque Psoriasis
POSTED: February 17, 2021
In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
